Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson ’s Disease Associated with LRRK2 Pathogenic Mutations

Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2 LRRK2 mutations are one of the most common genetic drivers of Parkinson’s disease Targeting LRRK2 has the potential to impact the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials